- Home
- AIRJW vs MRK Comparison
AIRJW vs MRK Comparison
Compare AIRJW & MRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AIRJW | MRK |
|---|---|---|
| Founded | N/A | 2000 |
| Country | United States | United States |
| Employees | 17 | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 260.2B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | AIRJW | MRK |
|---|---|---|
| Price | $0.85 | $106.86 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 15 |
| Target Price | N/A | ★ $111.93 |
| AVG Volume (30 Days) | 19.1K | ★ 14.5M |
| Earning Date | 03-21-2025 | 02-03-2026 |
| Dividend Yield | N/A | ★ 3.18% |
| EPS Growth | N/A | ★ 58.08 |
| EPS | 4.07 | ★ 7.56 |
| Revenue | N/A | ★ $64,235,000,000.00 |
| Revenue This Year | N/A | $1.98 |
| Revenue Next Year | N/A | $4.94 |
| P/E Ratio | ★ $2.05 | $14.13 |
| Revenue Growth | N/A | ★ 1.68 |
| 52 Week Low | $1.11 | $73.31 |
| 52 Week High | $1.32 | $107.05 |
Technical Indicators
Market Signals| Indicator | AIRJW | MRK |
|---|---|---|
| Relative Strength Index (RSI) | 52.69 | 70.67 |
| Support Level | $0.73 | $96.79 |
| Resistance Level | $1.02 | $100.94 |
| Average True Range (ATR) | 0.10 | 2.34 |
| MACD | 0.04 | 0.33 |
| Stochastic Oscillator | 67.84 | 96.13 |
Price Performance
Historical ComparisonAbout AIRJW Montana Technologies Corporation Warrant
AirJoule Technologies Corp is the developer of AirJoule, an atmospheric water harvesting technology that provides efficient and sustainable air dehumidification and pure water from air. AirJoule can also enable transformative HVAC products to help customers save money on their energy bills while reducing environmental impact.
About MRK Merck & Company Inc. (new)
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).